Cargando…

Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case–control study

OBJECTIVES: The study aims to compare the risk of chronic kidney diseases (CKDs) between patients with schizophrenia using first and second-generation antipsychotics. SETTING: Datasets of 2000–2013 National Health Insurance in Taiwan were used. PARTICIPANTS: The National Health Insurance reimburseme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hsien-Yi, Huang, Charles Lung-Cheng, Feng, I Jung, Tsuang, Hui-Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988075/ https://www.ncbi.nlm.nih.gov/pubmed/29794090 http://dx.doi.org/10.1136/bmjopen-2017-019868

Ejemplares similares

Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study
por: Højlund, Mikkel, et al.
Publicado: (2020)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari, Sulaiman, et al.
Publicado: (2015)

Antipsychotic Medications and Risk of Acute Coronary Syndrome in Schizophrenia: A Nested Case-Control Study
por: Liu, Hsing-Cheng, et al.
Publicado: (2016)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
por: Mahmoud, Ahmed, et al.
Publicado: (2011)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case–control study
por: Ikuta, Keiko, et al.
Publicado: (2021)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang, Xinyu, et al.
Publicado: (2019)

Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia
por: Jiang, Ping, et al.
Publicado: (2021)

Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
por: Haddad, Chadia, et al.
Publicado: (2023)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study
por: Weng, Shuo-Chun, et al.
Publicado: (2017)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Yeh, Tzu-Pei, et al.
Publicado: (2021)

Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
por: Kang, Seung-Gul, et al.
Publicado: (2021)

Features of childhood cancer in primary care: a population-based nested case–control study
por: Dommett, R M, et al.
Publicado: (2012)

Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study
por: Royle, J A, et al.
Publicado: (2011)

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Reproductive factors and risk of oesophageal cancer, a population-based nested case–control study in Sweden
por: Lu, Y, et al.
Publicado: (2012)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics
por: Oh, Jee-Eun, et al.
Publicado: (2012)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia
por: Washida, Kenji, et al.
Publicado: (2013)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
por: Fulone, Izabela, et al.
Publicado: (2021)

Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2021)

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
por: Fabrazzo, Michele, et al.
Publicado: (2022)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

History of kidney stones and risk of chronic kidney disease: a meta-analysis
por: Shang, Weifeng, et al.
Publicado: (2017)

Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study
por: Heinonen, Essi, et al.
Publicado: (2022)

Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_64nl0fd678hapduggsr9lc0rd1